Literature DB >> 24045720

Immortal time bias in the study of stillbirth risk factors: the example of gestational diabetes.

Jennifer A Hutcheon1, Verena Kuret, K S Joseph, Yasser Sabr, Kenneth Lim.   

Abstract

BACKGROUND: Current understanding of the increased risk for stillbirth in gestational diabetes mellitus is often based on large cohort studies in which the risk of stillbirth in women with this disease is compared with the risk in women without. However, such studies could be susceptible to immortal time bias because, although many cohorts begin at 20 weeks' gestation, pregnancies must "survive" until 24-28 weeks in order to be screened and diagnosed with gestational diabetes.
METHODS: We describe the theoretical potential for immortal time bias in studies of stillbirth and gestational diabetes and then quantify the magnitude of the bias using 2006 United States vital statistics data.
RESULTS: Although gestational diabetes was protective against stillbirth when including all births (relative risk = 0.88 [95% confidence interval = 0.79-0.99]), restricting analyses to births at >28 weeks' gestation reversed the effect and diabetes became associated with an increased risk of stillbirth (1.25 [1.11-1.41]).
CONCLUSION: Immortal time before diagnosis of gestational diabetes may bias our understanding of the stillbirth risk associated with this condition.

Entities:  

Mesh:

Year:  2013        PMID: 24045720     DOI: 10.1097/EDE.0b013e3182a6d9aa

Source DB:  PubMed          Journal:  Epidemiology        ISSN: 1044-3983            Impact factor:   4.822


  9 in total

1.  The prediction of fetal death with a simple maternal blood test at 20-24 weeks: a role for angiogenic index-1 (PlGF/sVEGFR-1 ratio).

Authors:  Tinnakorn Chaiworapongsa; Roberto Romero; Offer Erez; Adi L Tarca; Agustin Conde-Agudelo; Piya Chaemsaithong; Chong Jai Kim; Yeon Mee Kim; Jung-Sun Kim; Bo Hyun Yoon; Sonia S Hassan; Lami Yeo; Steven J Korzeniewski
Journal:  Am J Obstet Gynecol       Date:  2017-10-13       Impact factor: 8.661

Review 2.  The association between gestational diabetes and stillbirth: a systematic review and meta-analysis.

Authors:  Patricia Lemieux; Jamie L Benham; Lois E Donovan; Nadia Moledina; Christy Pylypjuk; Jennifer M Yamamoto
Journal:  Diabetologia       Date:  2021-10-21       Impact factor: 10.122

3.  Invited Commentary: Influenza, Influenza Immunization, and Pregnancy-It's About Time.

Authors:  Jennifer A Hutcheon; David A Savitz
Journal:  Am J Epidemiol       Date:  2016-07-22       Impact factor: 4.897

4.  Gestational age specific stillbirth risk among Indigenous and non-Indigenous women in Queensland, Australia: a population based study.

Authors:  Ibinabo Ibiebele; Michael Coory; Gordon C S Smith; Frances M Boyle; Susan Vlack; Philippa Middleton; Yvette Roe; Vicki Flenady
Journal:  BMC Pregnancy Childbirth       Date:  2016-07-15       Impact factor: 3.007

5.  Trends in Obstetric Intervention and Pregnancy Outcomes of Canadian Women With Diabetes in Pregnancy From 2004 to 2015.

Authors:  Amy Metcalfe; Yasser Sabr; Jennifer A Hutcheon; Lois Donovan; Janet Lyons; Jason Burrows; K S Joseph
Journal:  J Endocr Soc       Date:  2017-11-20

6.  Gestational diabetes and adverse perinatal outcomes from 716,152 births in France in 2012.

Authors:  Cécile Billionnet; Delphine Mitanchez; Alain Weill; Jacky Nizard; François Alla; Agnès Hartemann; Sophie Jacqueminet
Journal:  Diabetologia       Date:  2017-02-15       Impact factor: 10.122

7.  Educational note: addressing special cases of bias that frequently occur in perinatal epidemiology.

Authors:  Andreas M Neophytou; Marianthi-Anna Kioumourtzoglou; Dana E Goin; Kristin C Darwin; Joan A Casey
Journal:  Int J Epidemiol       Date:  2021-03-03       Impact factor: 7.196

8.  Prediction of stillbirth in women with overweight or obesity-A register-based cohort study.

Authors:  H Åmark; M Westgren; M Persson
Journal:  PLoS One       Date:  2018-11-19       Impact factor: 3.240

9.  A Clinical Update on Gestational Diabetes Mellitus.

Authors:  Arianne Sweeting; Jencia Wong; Helen R Murphy; Glynis P Ross
Journal:  Endocr Rev       Date:  2022-09-26       Impact factor: 25.261

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.